Accurate detection of somatic variants in tumors is of critical importance and remains challenging. Current methods typically require matched normal samples for reliable detection, which are often unavailable in real-world research and clinical scenarios. Without a matched normal sample, more proficient algorithms are required to distinguish true somatic variants from germline variants and technical artifacts. However, existing tumor-only somatic variant callers that were designed for short-read sequencing data are not able to work well with long-read data. To fill the gap, we present ClairS-TO, a deep-learning-based method for long-read tumor-only somatic variant calling. ClairS-TO uses an ensemble of two disparate neural networks trained from the same samples but for opposite tasks—how likely/not likely a candidate is a somatic variant. Benchmarks using COLO829 and HCC1395 cancer cell lines show that ClairS-TO outperforms DeepSomatic and smrest in ONT and PacBio long-read data. ClairS-TO is also applicable to short-read data and outperforms Mutect2, Octopus, Pisces, and DeepSomatic. Extensive experiments across various sequencing coverages, variant allelic fractions, and tumor purities support that ClairS-TO is a reliable tool for somatic variant discovery. ClairS-TO is open-source, available at https://github.com/HKU-BAL/ClairS-TO . The accurate detection of somatic variants in cancer without matched normal controls remains challenging, particularly for long-read sequencing data. Here, the authors develop ClairS-TO, a deep learning method for long-read tumour-only somatic variant calling that outperforms similar algorithms and can also work with short-read sequencing data.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.